323 related articles for article (PubMed ID: 1185108)
21. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
22. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.
Fearon DT; Austen KF; Ruddy S
J Exp Med; 1973 Dec; 138(6):1305-13. PubMed ID: 4202731
[TBL] [Abstract][Full Text] [Related]
23. Initiation of C3 cleavage in the alternative complement pathway.
Fearon DT; Austen KF
J Immunol; 1975 Nov; 115(5):1357-61. PubMed ID: 809512
[TBL] [Abstract][Full Text] [Related]
24. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
[TBL] [Abstract][Full Text] [Related]
26. A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components.
Hammer CH; Abramovitz AS; Mayer MM
J Immunol; 1976 Sep; 117(3):830-4. PubMed ID: 956655
[TBL] [Abstract][Full Text] [Related]
27. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
28. Binding of components of the properdin system to cultured human lymphoblastoid cells and B lymphocytes.
Theofilopoulos AN; Perrin LH
J Exp Med; 1976 Feb; 143(2):271-89. PubMed ID: 1082488
[TBL] [Abstract][Full Text] [Related]
29. Reversible activation of proactivator (factor B) of the alternative pathway without cleavage of the molecule.
Day NK; Schreiber RD; Götze O; Müller-Eberhard HJ
Scand J Immunol; 1976; 5(6-7):715-20. PubMed ID: 981969
[TBL] [Abstract][Full Text] [Related]
30. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
31. Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.
Vogt W; Schmidt G; Dieminger L; Lynen R
Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(5):440-55. PubMed ID: 126576
[TBL] [Abstract][Full Text] [Related]
32. Guinea pig erythrocytes, after their contact with influenza virus, acquire the ability to activate the human alternative complement pathway through virus-induced desialation of the cells.
Lambré CR; Kazatchkine MD; Maillet F; Thibon M
J Immunol; 1982 Feb; 128(2):629-34. PubMed ID: 6459381
[TBL] [Abstract][Full Text] [Related]
33. Properdin factor D: characterization of its active site and isolation of the precursor form.
Fearon DT; Austen KF; Ruddy S
J Exp Med; 1974 Feb; 139(2):355-66. PubMed ID: 4855753
[TBL] [Abstract][Full Text] [Related]
34. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
Stitzel AE; Spitzer RE
J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
[No Abstract] [Full Text] [Related]
35. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
38. A molecular basis of activation of the alternative pathway of human complement.
Austen KF; Fearon DT
Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
[TBL] [Abstract][Full Text] [Related]
39. Binding of activated properdin to untreated erythrocytes: a new function of activated properdin.
Konno T; Hirai H; Tamura N
Immunology; 1978 Feb; 34(2):207-15. PubMed ID: 627406
[TBL] [Abstract][Full Text] [Related]
40. Reaction of an activated complex of guinea-pig complement components, C56, with unsensitized erythrocytes and with erythrocytes carrying C3b molecule.
Tamura N; Baba AS
Immunology; 1976 Jul; 31(1):151-8. PubMed ID: 1027719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
